Enoda Cellworks

Enoda Cellworks is developing a novel platform technology to address the 'Cytokine Gap' in cell therapy, where the inability to safely and effectively harness cytokine signals limits therapeutic durability. Its core innovation is the MIMIC synthetic receptor architecture, which links any Signal 3 cytokine to a clinically relevant input, enabling high-throughput screening of cytokine functions and the engineering of cells with enhanced, non-toxic therapeutic programs. The company operates as a preclinical-stage platform biotech, seeking partnerships to apply its technology across various cell therapy modalities, from CAR-Ts to stem cells, to expand the scope of curable diseases.

MIMIC (Modular Immune-cytokine Integration Circuit) platform: a library of synthetic cytokine receptors that link any Signal 3 cytokine to a shared input, enabling high-throughput functional screening and engineering of non-toxic, optimized cytokine programs into cell therapies.

Enoda competes with other companies engineering cytokines (e.g., Synthekine, Senti Bio) and developing synthetic biology platforms for cell therapy (e.g., Arsenal Bio, Cell Design Labs). It also competes with large biopharma companies with internal cell therapy engineering capabilities. Differentiation hinges on the unique biophysical design of its MIMIC receptors and its high-throughput screening approach to the Signal 3 landscape.